Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Long Hill Capital Raises $300 Million for Third China Healthcare Fund

publication date: Apr 5, 2021

Long Hill Capital, a China healthcare venture firm, closed its third fund with more than $300 million in committed capital. Founded in 2016, Long Hill has now raised over $800 million. As with the earlier two funds, the firm plans to continue investing mainly in early stage healthcare and longevity companies, with some capital allocated to select growth-stage investments. Long Hill, which has offices in Shanghai and Beijing, notes that in 2050, more than 50% of China's citizens will be over the age of 50. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital